Loading
Life sciences · Journal article
Cancer Nanotechnology · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Lipid nanoparticles (LNPs) have emerged as the most clinically validated nanocarrier platform in oncology, transitioning from liposomal chemotherapy to the cornerstone of mRNA-based therapeutics. This review critically examines the evolving LNP landscape with a deliberate focus on p53, the tumour suppressor directly mutated or functionally silenced via pathway dysregulation in over half of human cancers and a unifying therapeutic target across diverse tumour types. We analyse LNP platform design, physicochemical properties, and structure-activity relationships that govern encapsulation, stability, and release. A dedicated section synthesizes p53-directed nucleic acid strategies delivered by LNPs, including p53 mRNA for wild-type restoration, siRNA for mutant p53 silencing, miR-34a mimics engaging the p53 downstream axis, and CRISPR-Cas9 components for TP53 correction. The review evaluates passive and active targeting, stimuli-responsive release mechanisms responsive to tumour microenvironmental cues, and the integration of p53 nanotherapy with immune checkpoint blockade. Clinical translation is appraised through key 2020–2026 milestones, notably the KEYNOTE-942 trial of personalized neoantigen mRNA-4157, which clinically validates the mRNA-LNP platform in oncology, alongside emerging preclinical and early exploratory p53 mRNA-LNP programs in hepatocellular carcinoma, non-small cell lung cancer, and pancreatic cancer. Persistent challenges, including liver-dominant biodistribution, anti-PEG immunogenicity, manufacturing scalability, and regulatory complexity, are discussed alongside artificial intelligence-guided lipid discovery and biomimetic approaches. By reframing LNP development around p53 biology, this review highlights how tumour-suppressor restoration offers a mechanistically coherent strategy to enhance therapeutic index, reprogram the tumour immune microenvironment, and extend LNP clinical benefit beyond the liver compartment across diverse tumour types. The synthesis indicates that p53-focused LNP engineering represents a convergent opportunity to unify diverse cancer nanomedicine efforts under a single, biologically grounded therapeutic paradigm.